After the breakthrough of trastuzumab,12 other compounds targeting ErbB members including pertuzumab,13, 14 trastuzumab emtansine,15 and pyrotinib8 have been confirmed to be effective in HER2‐positive patients with metastatic BC. This evidence concerns the gene EGFR and breast cancer.